Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Cisplatin and Docetaxel in NSCLC
NCT00582634Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Sep 2004
- Primary completion
- Dec 2007
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and Cisplatin micelle injection (HA132) in non-small cell lung cancer (NSCLC), sponsored by University of Wisconsin–Madison. Primary endpoints: Time to progression at 36 months, Overall survival at 36 months and 1 more. Started Sep 2004; status: completed.
02
Drugs
docetaxelCisplatin micelle injection (HA132)
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00582634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00582634.